Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon®) on rat prostate hyperplasia induced by hyperprolactinemia: Comparison with finasteride

Prostate

Volumn 43, Issue 1, 2000, Pages 49-58

  Van Coppenolle, Fabien ^a   Le Bourhis, Xuefen ^b   Carpentier, Françoise ^c   Delaby, Geoffrey ^a   Cousse, Henri ^d   Raynaud, Jean Pierre ^e   Dupouy, Jean Paul ^f   Prevarskaya, Natalia ^a  

^a Université des Sciences et Technologies de Lille   (France)

^b Serv d'Hydrobiologie d   (France)

^c CENTRE HOSPITALIER DE ROUBAIX   (France)

^d INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f UNIV LILLE   (France)

Author keywords

Androgens; Finasteride; LSESR; Prolactin; Rat prostate hyperplasia

Indexed keywords

ANDROGEN; FINASTERIDE; PROLACTIN; SABAL EXTRACT; SULPIRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HISTOLOGY; HORMONE DETERMINATION; HORMONE INHIBITION; HYPERPROLACTINEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; WEIGHT;

ANDROGEN ANTAGONISTS; ANIMALS; ENZYME INHIBITORS; FINASTERIDE; HYPERPROLACTINEMIA; MALE; ORGAN SIZE; PLANT EXTRACTS; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RATS, WISTAR; SERENOA;

EID: 0034027443     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000401)43:1<49::AID-PROS7>3.0.CO;2-J     Document Type: Article

References (57)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132: 474-479.
2. Walsh PC. Benign prostatic hyperplasia: etiological considerations. Proc Clin Biol Res 1984;145:1-25.
3. Horton R. Benign prostatic hyperplasia: new insights. J Clin Endocrinol Metab 1992;74:504.
4. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231-240.
5. Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D'Eramo G, Di Nicola S, Toscano V. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998:37:77-83.
6. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan D, Pappas F, Taylor A, Binkowitz B. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992:327:1185-1191.
7. George FW, Wilson JD. Sex determination and differentiation. In: Knobil E, Neill JD, editors. The physiology of reproduction. New York: Raven Press; 1994. p 3-28.
8. Boccon-Gibot L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997;32:391-395.
9. Limonta P, Morett RM, Dondi D, Montagnani Marelli M, Motta M. Androgen-dependent prostatic tumors: biosynthesis and possible actions of LHRH. J Steroid Biochem Mol Biol 1994;49: 347-350.
10. Vacher P. Gn-RH agonist in the treatment of prostatic carcinoma. Biomed Pharmacother 1995;49:325-331.
11. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab 1983;57:71-77.
12. Nankin HR, Calkins JH. Decreased bioavailable testosterone in aging normal and impotent men. J Clin Endocrinol Metab 1986; 63:1418-1420.
13. Hammond GL, Kontturi M, Maattala P, Puukka M, Vihko R. Serum FSH, LH and prolactin in normal males and patients with prostatic diseases. Clin Endocrinol 1977;7:129-135.
14. Vekemans M, Robyn C. Influence of age in serum prolactin levels in women and men. Br Med J 1975:4:738-739.
15. Costello LC, Franklin RB. Effect of prolactin on the prostate. Prostate 1994;24:162-166.
16. Wennbo H, Kindblom J, Isaksson OGP, Tornell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 1997;138:4410-4415.
17. Lane KE, Leav I, Ziar J, Bridges RS, Rand WM, Ho SM. Suppression of testosterone and estradiol-17β-induced dysplasia in the dorsolateral prostate of Noble rats by bromocriptine. Carcinogenesis 1997;18:1505-1510.
18. Tangbanluekal L, Robinette CL. Prolactin mediates estradiol-induced inflammation in the lateral prostate of Wistar rats. Endocrinology 1993;132:2407-2416.
19. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 1997; 99:618-627.
20. Nevalainen MT, Valve EM, Ahonen T, Yagi A, Paranko J, Harkonen PL. Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture. FASEB J 1997;11:297-307.
21. Farnsworth WE. Prolactin effect on the permeability of human benign hyperplastic prostate to testosterone. Prostate 1988;12: 221-229.
22. Prins GS. Prolactin influence of cytosol and nuclear androgen receptors in the ventral, dorsal and lateral lobes of the rat prostate. Endocrinology 1987;120:1457-1464.
23. Smith C, Assimos D, Lee C, Grayhack JT. Metabolic action of prolactin in regressing prostate: independent of androgen action. Prostate 1985;6:49-59.
24. Reiter E, Lardinois S, Klug M, Sente B, Hennuy B, Bruyninx M, Closset J, Hennen G. Androgen-independent effects of prolactin on the different lobes of the immature rat prostate. Mol Cell Endocrinol 1995;112:113-122.
25. Kledzik GS, Marshall S, Campbell GA, Gelato M, Meites J. Effects of castration, testosterone, estradiol, and prolactin on specific prolactin-binding activity in ventral prostate of male rats. Endocrinology 1976;98:373-379.
26. Aragona C, Bonnet HG, Friesen HG. Localization of prolactin binding in prostate and testis: the role of serum prolactin concentration on the testicular LH receptor. Acta Endocrinol (Copenh) 1977;84:402-409.
27. Fekete A. Receptors for luteinizing hormone-realizing hormone, somatostatine, prolactin and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate 1979;14:191-208.
28. Robaire B, Ewing LL, Irby DC, Desjardins C. Interactions of testosterone and estradiol-17β on the reproductive tract of the male rate. Biol Reprod 1979;21:455-463.
29. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984;5:545-557.
30. Jahn GA, Deis RP. Stress-induced prolactin release in female, male and androgenized rats: influence of progesterone treatment. Endocrinology 1986;110:423-428.
31. Donnerer J, Lembeck F. Different control of the adrenocorticotropin-corticosterone response and of prolactin secretion during cold stress, anesthesia, surgery, and nicotine injection in the rat: involvement of capsaicin-sensitive sensory neurons. Endocrinology 1990;126:921-926.
32. Fujikawa T, Soya H, Yoshizato H, Sakaguchi K, Doh-Ura K, Tanaka M, Nakashima K. Restraint stress enhances the gene expression of prolactin receptor long form at the choroid plexus. Endocrinology 1995;136:5608-5613.
33. Robinette C. Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 1988;12: 271-286.
34. Paubert-Braquet M, Richardson FO, Servent-Saez N, Gordon WC, Monge MC, Bazan NG, Authie D, Braquet P. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargment in the rat. Pharmacol Res 1996;34:171-179.
35. Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P. Effect of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostatic biopsies. Europ Urol 1998;3:340-347.
36. Bayne CW, Grant ES, Chapman K, Habib FK. Characterisation of a new co-culture model for BPH which expresses 5α-reductase type 1 and 2: the effects of Permixon on DHT formation [abstract]. J Urol 1997;157:194.
37. Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9:379-395.
38. Carilla E, Briley M, Fauran F, Sultan C, Duvilliers C. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem 1984;20:521-523.
39. Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P. Effect of the lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated proliferation of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukotrienes Essent Fatty Acids 1997;57:299-304.
40. Casarosa C, Cosci di Coscio M, Fratta M. Lack of effects of a lipidosterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone. Clin Ther 1988;10:585-588.
41. Prahalada S, Rhodes L, Grossman SJ, Heggan D, Keenan D, Keenan KP, Cukierski MA, Hoe CM, Berman C, van Zwieten MJ. Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor. Prostate 1998;35:157-164.
42. Price D. Comparative aspects of development and structure in the prostate. Natl Cancer Inst Monogr 1963;12:351-369.
43. Debeljuk L, Rozados R, Daskal H, Velez V, Mancini AM. Acute and chronic effects of sulpiride on serum prolactin and gonadotropin levels in castrated male rats (38581). Proc Soc Biol Med 1975;148:550-552.
44. Nakagawa K, Obara T, Matsubara M, Kubo M. Relationship of changes in serum concentrations of prolactin and testosterone during dopaminergic modulation in males. Clin Endocrinol 1982;17:345-352.
45. Span PN, Voller MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS. Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase isoenzyme activity in the human prostate. J Urol 1999;161:332-337.
46. Rittmaster RS, Manning AP, Stuart Wright A, Thomas LN, Whitefield S, Norman RW, Lazier CB, Rowden G. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5α-reductase inhibitor finasteride. Endocrinology 1995;136:741-748.
47. Strauch G, Perles P, Vergult G, Gabriel M, Gibelin B, Cummings S, Malbecq W, Malice MP. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994;26:247-252.
48. Vacher P, Prevarskaya N, Skryma R, Audy MC, Vacher AM, Odessa MF, Dufy B. The lipido-sterolic extract of Serenoa repens interferes with prolactin receptor signal transduction. J Biomed Sci 1995;2:357-365.
49. Neill JD, Reichert LD. Control of the proestrus surge of prolactin and luteinizing hormone secretion by oestrogens in the rat. Endocrinology 1971;89:1448-1453.
50. Shin SH. Estradiol generates pulses of prolactin secretion in castrated male rats. Neuroendocrinology 1979;29:270-275.
51. Di Silverio F, D'Eramo G, Lubrano C, Flammia GP, Sciarra A, Palma E, Caponera M, Sciarra F. Evidence that Serenoa repens extract displays an anti-estrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992;21:309-314.
52. Yatani R, Kusano I, Shiraishi T, Miura S, Takanari H, Liu PI. Elevated prolactin level in prostates with latent carcinoma. Ann Clin Lab Sci 1987;17:178-182.
53. Rana A, Habib FK, Halliday P, Ross M, Wild R, Elton RA, Chisholm GD. A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Eur J Cancer 1995;31:871-875.
54. Jeromin L. The serum levels of testosterone and prolactin in patients with prostatic carcinoma treated with various doses of fostrolin and bromocriptine. Int Urol Nephrol 1982;14:51-56.
55. Jacobi GH, Sinterhauf K, Kurth KH, Altwein JE. Testosterone metabolism in patients with advanced carcinoma of the prostate: a comparative in vivo study of the effects of oestrogen and antiprolactin. Urol Res 1978;6:159-165.
56. Van Poppel H, Boeckx G, Westelinck KJ, Vereecken RL, Baert L. The efficacy of bromocriptine in benign prostatic hypertrophy. A double-blind study. Br J Urol 1987;60:150-152.
57. Matos-Ferreira A, Corte-Real J, Palma J, Durao V. The effect of bromocriptine in benign prostatic hypertrophy and vesico-sphincteric dynamics. Br J Urol 1987;60:143-149.